Abstract
Current clinical practice guidelines recommend dosing anti-tuberculosis drugs according to ideal body weight and provide dosing caps for most first-line agents. However, this recommendation may be placing corpulent patients with tuberculosis at risk as increased total body weight is associated with an increased risk of clinical failure. Patients with diabetes are at an increased risk of developing tuberculosis and typically weigh more than patients with tuberculosis alone. All these factors in-combination stress the importance of evaluating the effect of weight on the pharmacokinetics of first-line anti-tuberculosis drugs.
Multiple studies suggest the use of total body weight based dosing for rifampin. Less data are available for pyrazinamide and ethambutol, but both appear to be candidates for total body weight based dosing. The study evaluating levofloxacin concluded that no adjustment is required. However, the larger variability in obese patients is concerning as to whether “one size fits all” dosing is optimal for levofloxacin. The vast majority of the isoniazid’s pharmacokinetic variability is due to NAT2*4 status. However, more extensive analysis of slow and fast metabolizers is needed to determine the effect of weight within each subgroup. Moxifloxacin does not appear to be affected by weight, but doses of at least 800 mg are likely needed to optimize its pharmacokinetic/pharmacodynamic target attainment.
Future pharmacokinetic evaluations should focus on recruiting a wide range of patient weights. These analyses should take advantage of the full weight distribution instead of arbitrarily dichotomizing patients into obese vs. non-obese persons. A subsequent evaluation of the safety and effectiveness of optimized dosing regimens is needed.
Keywords: Dose optimization, ethambutol, isoniazid, obesity, pharmacokinetics, pyrazinamide, rifampin, tuberculosis.
Current Pharmaceutical Design
Title:Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World
Volume: 21 Issue: 32
Author(s): Ronald G. Hall II
Affiliation:
Keywords: Dose optimization, ethambutol, isoniazid, obesity, pharmacokinetics, pyrazinamide, rifampin, tuberculosis.
Abstract: Current clinical practice guidelines recommend dosing anti-tuberculosis drugs according to ideal body weight and provide dosing caps for most first-line agents. However, this recommendation may be placing corpulent patients with tuberculosis at risk as increased total body weight is associated with an increased risk of clinical failure. Patients with diabetes are at an increased risk of developing tuberculosis and typically weigh more than patients with tuberculosis alone. All these factors in-combination stress the importance of evaluating the effect of weight on the pharmacokinetics of first-line anti-tuberculosis drugs.
Multiple studies suggest the use of total body weight based dosing for rifampin. Less data are available for pyrazinamide and ethambutol, but both appear to be candidates for total body weight based dosing. The study evaluating levofloxacin concluded that no adjustment is required. However, the larger variability in obese patients is concerning as to whether “one size fits all” dosing is optimal for levofloxacin. The vast majority of the isoniazid’s pharmacokinetic variability is due to NAT2*4 status. However, more extensive analysis of slow and fast metabolizers is needed to determine the effect of weight within each subgroup. Moxifloxacin does not appear to be affected by weight, but doses of at least 800 mg are likely needed to optimize its pharmacokinetic/pharmacodynamic target attainment.
Future pharmacokinetic evaluations should focus on recruiting a wide range of patient weights. These analyses should take advantage of the full weight distribution instead of arbitrarily dichotomizing patients into obese vs. non-obese persons. A subsequent evaluation of the safety and effectiveness of optimized dosing regimens is needed.
Export Options
About this article
Cite this article as:
Hall II G. Ronald, Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150625120936
DOI https://dx.doi.org/10.2174/1381612821666150625120936 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hybrid Docking-QSAR Studies of 1, 4-dihydropyridine-3, 5-Dicarboxamides as Potential Antitubercular Agents
Current Computer-Aided Drug Design Biospecies Capture and Detection at Low Concentration
Micro and Nanosystems Synthesis, Anti-cancer Activity and Mechanism Study of 6-Mercapto-purine Derivatives
Letters in Drug Design & Discovery Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Crosstalk between Behavior and Immune System During the Prodromal Stages of Alzheimer`s Disease
Current Pharmaceutical Design The Evolution of Clostridium difficile Infection in Cancer Patients: Epidemiology, Pathophysiology, and Guidelines for Prevention and Management
Recent Patents on Anti-Infective Drug Discovery Meet Our Editorial Board Member:
Current HIV Research Methods for Diagnosis of Human Pulmonary Tuberculosis (Mini-Review)
Applied Clinical Research, Clinical Trials and Regulatory Affairs Cyanide Detoxifying Enzyme: Rhodanese
Current Biotechnology Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry Patenting of Nanopharmaceuticals in Drug Delivery: No Small Issue
Recent Patents on Drug Delivery & Formulation Metabolism Evolution Based on Network Degrees of Orthologous Enzymes
Current Topics in Medicinal Chemistry Recent Advances and Future Perspectives of Triazole Analogs as Promising Antiviral Agents
Mini-Reviews in Medicinal Chemistry Bis-coumarin Derivatives and Their Biological Activities
Current Topics in Medicinal Chemistry Fragment Pharmacophore-Based Screening: An Efficient Approach for Discovery of New Inhibitors of Toll-Like Receptor 5
Combinatorial Chemistry & High Throughput Screening Applications of Barbier Type Reactions in Carbohydrate Chemistry
Current Organic Synthesis On the Contribution of Molecular Topology to Drug Design and Discovery
Current Computer-Aided Drug Design Recent Advances in Nanoparticle Carriers for Coordination Complexes
Current Topics in Medicinal Chemistry Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer
Current Cancer Drug Targets